Iluvien delays recurrence of noninfectious posterior uveitis over 3 years

Three-year data for Iluvien found a single implant delayed recurrence of noninfectious posterior uveitis and reduced uveitis symptoms, according to a press release from Alimera Sciences.
The phase 3 clinical trial showed the median time to first recurrence of noninfectious uveitis affecting the posterior of the eye was 657 days, or 94 weeks, in patients treated with Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg) compared with 70.5 days, or 10 weeks, in those treated with sham (P

Global Glaucoma Clinical Trial Pipeline Highlights, 2019 Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global Glaucoma Clinical Trial Pipeline Highlights – 2019” report has been added to ResearchAndMarkets.com’s offering. Glaucoma Pipeline Highlights – 2019, provides most up-to-date information on key pipeline products in the global Glaucoma market. It covers emerging therapies for Glaucoma in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identi